Comparative Pharmacology

Head-to-head clinical analysis: SULFANILAMIDE versus TRIPLE SULFA.

Peer-Reviewed Evidence

Differential Analysis

SULFANILAMIDE vs TRIPLE SULFA

Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.

SULFANILAMIDE

Sulfonamide Antibiotic

Category C

TRIPLE SULFA

Sulfonamide Antibiotic

Category C

Head-to-Head

Clinical Matrix

Mechanism of Action

Competitive inhibitor of dihydropteroate synthase, blocking para-aminobenzoic acid (PABA) incorporation into dihydropteroic acid, thereby inhibiting bacterial folic acid synthesis.

Inhibits bacterial dihydropteroate synthase (DHPS) and dihydrofolate reductase (DHFR), blocking folate synthesis essential for nucleic acid production.

Clinical Dosing

2-4 g orally initially, then 2-4 g every 4-6 hours, not to exceed 12 g/day; intravenous: 4-8 g/day in divided doses every 6-8 hours.

1 g orally every 12 hours for 10 days (as sulfadiazine, sulfamethazine, and sulfamerazine combination).

Direct Interaction

None Documented

Half-Life

Terminal elimination half-life: 7-12 hours; prolonged in renal impairment (up to 24-48 hours).

Other Significant Interactions

Clinical Note

moderate

Sulfanilamide + Fesoterodine

"The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Sulfanilamide."

Clinical Note

moderate

Sulfanilamide + Atorvastatin

"The risk or severity of adverse effects can be increased when Sulfanilamide is combined with Atorvastatin."

Clinical Note

moderate

Sulfanilamide + Mecamylamine

"The risk or severity of adverse effects can be increased when Sulfanilamide is combined with Mecamylamine."

Clinical Note

moderate